Surprising recommendations for #HCV genotype 3. G/P 8 weeks for all non cirrhotic patients, irrespective RAS, HCV-RNA and fibrosis is difficult to understand, considering the results of ENDURANCE-3 trial (SVR 89% if F3, 88% if VL>=6MU and 75% with A30K) nejm.org/doi/full/10.10…
Conversely, SOF/VEL is not recommended in GT3 with cirrhosis, in spite of the fact that SVR was 91% in the Spanish study (PS-035 at this meeting) in the overall population and 96% in those with prior expericiece ilc-congress.eu/wp-content/upl…
It will be interesting to hear from @JMPawlotsky why the criteria used for both combinations were so different, but this is no good for the credibility of these guidelines
The recommendation of EBR/GZR 8 w for GT1b, despite only preliminary data being reported, and 3D 8w, a combination with more interactions and a more complicated dosing schedule, at the same level than G/P, SOF/LDV or SOF/VEL is also difficult to justify
• • •
Missing some Tweet in this thread? You can try to
force a refresh
